Beam Therapeutics Stock Analysis

BEAM Stock  USD 23.17  1.70  6.84%   
Beam Therapeutics is undervalued with Real Value of 34.93 and Target Price of 67.0. The main objective of Beam Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Beam Therapeutics is worth, separate from its market price. There are two main types of Beam Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Beam Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Beam Therapeutics is usually not traded on Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day. Beam Stock trading window is adjusted to America/New York timezone.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.

Beam Stock Analysis Notes

About 91.0% of the company shares are held by institutions such as insurance companies. The book value of Beam Therapeutics was currently reported as 11.58. The company recorded a loss per share of 1.6. Beam Therapeutics last dividend was issued on the February 4, 2014. The entity had 2:1 split on the October 26, 1990. Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. Beam Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 507 people. For more info on Beam Therapeutics please contact John MBA at 857 327 8775 or go to https://beamtx.com.

Beam Therapeutics Quarterly Total Revenue

7.41 Million

Beam Therapeutics Investment Alerts

Beam Therapeutics generated a negative expected return over the last 90 days
Beam Therapeutics has high historical volatility and very poor performance
The company reported the previous year's revenue of 377.71 M. Net Loss for the year was (132.53 M) with loss before overhead, payroll, taxes, and interest of (250.67 M).
Beam Therapeutics currently holds about 1.09 B in cash with (149.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.9.
Beam Therapeutics has a frail financial position based on the latest SEC disclosures
Over 91.0% of the company shares are held by institutions such as insurance companies
Latest headline from finance.yahoo.com: Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

Beam Therapeutics Upcoming and Recent Events

27th of February 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Beam Largest EPS Surprises

Earnings surprises can significantly impact Beam Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-11-10
2020-09-30-0.56-0.69-0.1323 
2023-11-08
2023-09-30-1.36-1.220.1410 
2020-08-12
2020-06-30-0.53-0.69-0.1630 
View All Earnings Estimates

Beam Therapeutics Environmental, Social, and Governance (ESG) Scores

Beam Therapeutics' ESG score is a quantitative measure that evaluates Beam Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Beam Therapeutics' operations that may have significant financial implications and affect Beam Therapeutics' stock price as well as guide investors towards more socially responsible investments.

Beam Stock Institutional Investors

Shares
Redmile Group, Llc2024-03-31
1.9 M
Temasek Holdings Ltd.2024-03-31
1.8 M
Geode Capital Management, Llc2024-03-31
1.6 M
T. Rowe Price Associates, Inc.2024-03-31
1.2 M
Bellevue Group Ag2024-03-31
1.2 M
Yiheng Capital Llc2024-03-31
845.5 K
Baillie Gifford & Co Limited.2024-03-31
752.4 K
Casdin Capital, Llc2024-03-31
675 K
Northern Trust Corp2024-03-31
659.2 K
Ark Investment Management Llc2024-03-31
8.2 M
Vanguard Group Inc2024-03-31
7.6 M
Note, although Beam Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Beam Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.05 B.

Beam Profitablity

The company has Profit Margin (PM) of (0.37) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (14.05) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $14.05.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.09)(0.10)
Return On Capital Employed(0.14)(0.13)
Return On Assets(0.09)(0.10)
Return On Equity(0.14)(0.14)

Management Efficiency

Beam Therapeutics has return on total asset (ROA) of (0.0844) % which means that it has lost $0.0844 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1609) %, meaning that it created substantial loss on money invested by shareholders. Beam Therapeutics' management efficiency ratios could be used to measure how well Beam Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 18th of June 2024, Return On Tangible Assets is likely to drop to -0.1. In addition to that, Return On Capital Employed is likely to grow to -0.13. At this time, Beam Therapeutics' Total Current Assets are very stable compared to the past year. As of the 18th of June 2024, Net Tangible Assets is likely to grow to about 885.7 M, while Non Current Assets Total are likely to drop about 193.3 M.
Last ReportedProjected for Next Year
Book Value Per Share 12.72  13.36 
Tangible Book Value Per Share 12.72  13.36 
Enterprise Value Over EBITDA(11.74)(12.33)
Price Book Value Ratio 2.14  2.25 
Enterprise Value Multiple(11.74)(12.33)
Price Fair Value 2.14  2.25 
Enterprise Value1.8 B3.5 B
The analysis of Beam Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Beam Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Beam Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Operating Margin
(14.05)
Profit Margin
(0.37)
Beta
1.884
Return On Assets
(0.08)
Return On Equity
(0.16)

Technical Drivers

As of the 18th of June 2024, Beam Therapeutics shows the mean deviation of 3.29, and Risk Adjusted Performance of (0.02). Beam Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Beam Therapeutics information ratio, and the relationship between the coefficient of variation and value at risk to decide if Beam Therapeutics is priced correctly, providing market reflects its regular price of 23.17 per share. Given that Beam Therapeutics has information ratio of (0.05), we suggest you to validate Beam Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Beam Therapeutics Price Movement Analysis

Execute Study
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Beam Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Beam Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Beam Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Beam Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Beam Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Beam Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Walsh Kathleen E a day ago
Acquisition by Walsh Kathleen E of 16532 shares of Beam Therapeutics at 34.33 subject to Rule 16b-3
 
Walsh Kathleen E 2 days ago
Acquisition by Walsh Kathleen E of 16532 shares of Beam Therapeutics at 34.33 subject to Rule 16b-3
 
Walsh Kathleen E 3 days ago
Acquisition by Walsh Kathleen E of 16532 shares of Beam Therapeutics at 34.33 subject to Rule 16b-3
 
Walsh Kathleen E few days ago
Acquisition by Walsh Kathleen E of 16532 shares of Beam Therapeutics at 34.33 subject to Rule 16b-3
 
Walsh Kathleen E over a week ago
Acquisition by Walsh Kathleen E of 16532 shares of Beam Therapeutics at 34.33 subject to Rule 16b-3
 
Walsh Kathleen E over a week ago
Acquisition by Walsh Kathleen E of 16532 shares of Beam Therapeutics at 34.33 subject to Rule 16b-3
 
Walsh Kathleen E over a week ago
Acquisition by Walsh Kathleen E of 16532 shares of Beam Therapeutics at 34.33 subject to Rule 16b-3
 
Fishman Mark over a week ago
Acquisition by Fishman Mark of 23114 shares of Beam Therapeutics at 24.49 subject to Rule 16b-3
 
Walsh Kathleen E over a week ago
Acquisition by Walsh Kathleen E of 16532 shares of Beam Therapeutics at 34.33 subject to Rule 16b-3
 
Walsh Kathleen E over two weeks ago
Acquisition by Walsh Kathleen E of 16532 shares of Beam TherapeuticsInc at 34.33 subject to Rule 16b-3
 
Walsh Kathleen E over two weeks ago
Acquisition by Walsh Kathleen E of 16532 shares of Beam TherapeuticsInc at 34.33 subject to Rule 16b-3
 
Walsh Kathleen E over three weeks ago
Acquisition by Walsh Kathleen E of 16532 shares of Beam TherapeuticsInc at 34.33 subject to Rule 16b-3

Beam Therapeutics Predictive Daily Indicators

Beam Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Beam Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Beam Therapeutics Corporate Filings

8K
10th of June 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
7th of June 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
ASR
28th of February 2024
Automatic Shelf Registration Statement under Rule 415 filed with the U.S. Securities and Exchange Commission (SEC)
ViewVerify
8K
27th of February 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
15th of February 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
13A
14th of February 2024
An amended filing to the original Schedule 13G
ViewVerify
13A
13th of February 2024
An amended filing to the original Schedule 13G
ViewVerify
13A
12th of February 2024
An amended filing to the original Schedule 13G
ViewVerify

Beam Therapeutics Forecast Models

Beam Therapeutics' time-series forecasting models are one of many Beam Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Beam Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Beam Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Beam Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Beam shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Beam Therapeutics. By using and applying Beam Stock analysis, traders can create a robust methodology for identifying Beam entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.35)(0.36)
Operating Profit Margin(0.47)(0.49)
Net Loss(0.35)(0.37)
Gross Profit Margin 0.95  0.99 

Current Beam Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Beam analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Beam analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
67.0Buy15Odds
Beam Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Beam analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Beam stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Beam Therapeutics, talking to its executives and customers, or listening to Beam conference calls.
Beam Analyst Advice Details

Beam Stock Analysis Indicators

Beam Therapeutics stock analysis indicators help investors evaluate how Beam Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Beam Therapeutics shares will generate the highest return on investment. By understating and applying Beam Therapeutics stock analysis, traders can identify Beam Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow232.8 M
Common Stock Shares Outstanding77.2 M
Total Stockholder Equity981.3 M
Tax Provision1000 K
Property Plant And Equipment Net237.8 M
Cash And Short Term Investments1.2 B
Cash435.9 M
Accounts Payable1.6 M
Net Debt-262.7 M
50 Day M A24.2188
Total Current Liabilities205.6 M
Other Operating Expenses554.2 M
Non Current Assets Total248.7 M
Non Currrent Assets Other2.1 M
Stock Based Compensation98.6 M

Additional Information and Resources on Investing in Beam Stock

When determining whether Beam Therapeutics is a strong investment it is important to analyze Beam Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Beam Therapeutics' future performance. For an informed investment choice regarding Beam Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.
You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.60)
Revenue Per Share
4.539
Quarterly Revenue Growth
(0.69)
Return On Assets
(0.08)
Return On Equity
(0.16)
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.